Management of Dyslipidemia

Overview

This 1.5 credit asynchronous course provides clinicians with practical, evidence-based guidance on the management of dyslipidemia using the latest 2026 ACC/AHA multisociety dyslipidemia guidelines and recent supporting literature.

The course emphasizes major practice-changing updates, including revised LDL-C targets, expanded use of non-statin therapies (e.g., PCSK9 inhibitors, inclisiran, bempedoic acid), and enhanced risk stratification approaches across diverse patient populations. Content integrates current recommendations for primary and secondary prevention, with a focus on individualized, risk-based treatment strategies.

Target Audience

This activity is intended for physicians, nurses, pharmacists, and other healthcare professionals.

Learning Objectives

  1. Identify key updates in the 2026 ACC/AHA multisociety dyslipidemia guidelines, including revised LDL-C targets and treatment thresholds.
  2. Assess cardiovascular risk using updated risk stratification tools across primary and secondary prevention populations.
  3. Implement stepwise, guideline-directed lipid-lowering strategies utilizing statins and non-statin therapies, including PCSK9 inhibitors, inclisiran, and bempedoic acid, to manage complex lipid cases.
  4. Apply effective patient counseling strategies and interprofessional care approaches to improve medication adherence, optimize cardiovascular risk reduction, and achieve long-term lipid control across patient populations.

Course summary

Available credit: 
  • 1.50 ACPE Pharmacist
  • 1.50 ACPE Pharmacy Technician
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Nursing Hours
  • 0.15 IACET CEUs
  • 1.50 IPCE
Course opens: 
11/10/2026
Course expires: 
11/10/2029

 Dave Dixon, PharmD

Dr. Dave Dixon is the Nancy and Ronald McFarlane Professor of Pharmacy and Chair of the Department of Pharmacotherapy & Outcomes Science at the Virginia Commonwealth University School of Pharmacy. He also holds a joint appointment as Professor of Internal Medicine in the Division of Cardiology at the VCU School of Medicine. Dr. Dixon's clinical and research work focuses on identifying and addressing gaps in the prevention and treatment of cardiovascular disease, with particular emphasis on hypertension and dyslipidemia. He has served on multiple writing groups for clinical practice guidelines and scientific statements and has authored nearly 200 peer-reviewed publications. Dr. Dixon is a Fellow of the American College of Cardiology, the American Heart Association, the American College of Clinical Pharmacy, and the National Lipid Association.

 Anurag Mehta, MD

Dr. Anurag Mehta is a physician-scientist and Assistant Professor of Medicine within the Division of Cardiology at the Emory University School of Medicine. As a preventive cardiologist at the Emory Heart & Vascular Center, his career is defined by a deep specialization in cardiovascular risk stratification, novel biomarkers, and global cardiovascular disease epidemiology. He has authored over 150 peer-reviewed publications in high-impact journals, including Circulation, Journal of the American College of Cardiology, European Heart Journal, Nature Reviews Cardiology, and JAMA Cardiology, with more than 6,500 citations (h-index 42).

Relevant Financial Relationships

Anurag Mehta has the following relevant financial relationships to disclose: institutional research grants from Novartis, Amgen and Eli Lilly. All relevant financial relationships have been mitigated through independent content review by Dave Dixon, who has no relevant financial relationships with ineligible companies. None of the planners for this activity have relevant financial relationships to disclose.

Anti-discrimination Policy

Dave Dixon, Anurag Mehta, the advisor, and course planners have agreed to our anti-discrimination policy that prohibits the inclusion of discriminatory language, graphics, or references on the basis of race, gender identity, age, color, national origin, physical or mental disability, or religion.

PHARMACISTS AND PHARMACY TECHNICIANS

Innovation Horizons is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Innovation Horizons designates this enduring material for:

ACPE Pharmacist: (1.5 Contact Hour) UAN: JA4008411-0000-26-016-H01-P

ACPE Pharmacy Technician: (1.5 Contact Hour) UAN: JA4008411-0000-26-016-H01-T

PHYSICIANS – AMA CREDIT DESIGNATION STATEMENT

Innovation Horizons designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMA PRA Category 1 Credit™

NURSES – ANCC CREDIT DESIGNATION STATEMENT

Innovation Horizons designates this enduring activity for a maximum of 1.5 ANCC contact hours. Nursing contact hours will be awarded for successful completion of program components based upon documented attendance and completion of evaluation materials

JOINT ACCREDITATION

In support of improving patient care, Innovation Horizons is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

IPCE CREDITS

This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.


MIPS

This activity is registered as a MIPS Improvement Activity (IA_PSPA_28). To qualify, learners must complete all activity components, including follow-up surveys. MIPS-eligible clinicians may attest in the CMS Quality Payment Program.

Available Credit

  • 1.50 ACPE Pharmacist
  • 1.50 ACPE Pharmacy Technician
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Nursing Hours
  • 0.15 IACET CEUs
  • 1.50 IPCE
Please login or register to take this course.

Required Hardware/Software

High-Speed Internet Connection

Adobe Reader for PDF file download

Browser:

  • This educational activity has been tested in the latest versions of Edge, Firefox, Safari, and Chrome browsers on Windows or Macintosh computers. 
  • The Safari, Firefox, or Chrome browsers are recommended for best results. 
  • The Internet Explorer browser is not recommended as it is no longer supported by Microsoft.